Filing Flows › Delcath Systems (DCTH) › Guidance & outlook
Delcath Systems (DCTH) guidance and outlook
Delcath Systems (DCTH) raised its guidance on Nov 9, 2026: Revenue $115M–$117M for FY2026; Gross margin 87%–89% for FY2026. Delcath Systems' 10-Q filed Nov 9, 2026 makes 13 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $115M–$117M | raised |
| Revenue | FY2026 | +41% | new |
| Gross margin | FY2026 | 87%–89% | raised |
From the earnings release filed Nov 9, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 9, 2026
- Solely for convenience and readability, trademarks, service marks and trade names, including logos, artwork and other visual displays, may appear in a non-traditional trademark usage manner, including without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to…
- • our estimates regarding sufficiency of our cash resources, anticipated capital requirements, future revenue and our need for additional financing;
- We have sufficient raw material and component constituent parts of the HEPZATO KIT to meet anticipated demand and we intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
- We expect that the publication will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States.
- We estimate that the total addressable market (“TAM”) for liver-dominant mCRC receiving third-line treatment is between 6,000 and 10,000 patients annually in the United States.
- By targeting this patient population, we aim to provide a novel treatment option for those with limited therapeutic alternatives.
- We expect approximately 90 patients will be enrolled in this randomized, controlled trial.
- We estimate that approximately 7,000 patients annually in the United States are affected by HER2-negative metastatic breast cancer with liver metastases and are candidates for third-line treatment.
- By focusing on this demographic, we intend to offer a novel therapeutic option to those patients with limited treatment alternatives.
- We expect our research and development expenses to increase for the foreseeable future relating to the costs required to complete these Phase 2 clinical trials.
- Our expected research and development expenses will consist primarily of:
- At this time, we cannot reasonably estimate or know the exact nature, timing and estimated costs of the efforts that will be necessary.
Delcath Systems' latest quarter
Delcath Systems, Q3 2026: revenue $35.1M (+71% year over year), operating margin 20.3%, net earnings $7.0M, operating cash flow $8.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Delcath Systems raise or lower its guidance?
Delcath Systems (DCTH) raised its guidance on Nov 9, 2026: Revenue $115M–$117M for FY2026; Gross margin 87%–89% for FY2026.
What does Delcath Systems expect?
Solely for convenience and readability, trademarks, service marks and trade names, including logos, artwork and other visual displays, may appear in a non-traditional trademark usage manner, including without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to… • our estimates regarding sufficiency of our cash resources, anticipated capital requirements, future revenue and our need for additional financing; We have sufficient raw material an
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.